Daiichi Sankyo Company, Limited (DSNKY) Stock Price & Analysis
Daiichi Sankyo Company, Limited (DSNKY) is trading at USD 17.83, down 1.44% today, as of October 23, 2026 at 16:23 UTC (US market open; quotes may be delayed), according to Nexqual market data.
DSNKY last closed at USD 18.09; today's session has ranged USD 17.83–17.92 on volume of 5,314 shares. Market capitalization is $32.44B, with a 52-week range of USD 14.98–26.8 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:42 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DSNKY.md
Key facts (DSNKY)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 23.35 (range 22–24.7).
- Total return with dividends: 1Y -33.5% vs S&P 500 +14.6%; 5Y -28.6% vs S&P 500 +77.3%.
- Next earnings: 2026-10-30, EPS estimate USD —, revenue estimate $566B.
Analysts (DSNKY)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 23.35 (low 22, high 24.7).
Total return (dividends reinvested) (DSNKY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -33.5% | -28.6% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -33.5% | -6.5% |
| Volatility (annualized) | 40.8% | 36.0% |
| Max drawdown | -43.7% (Oct 2025→Jun 2026) | -62.9% (Aug 2024→Jun 2026) |
DSNKY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $566.08B | — |
| Next quarter (ends Dec 2026) | — | — | — | $595.53B | — |
| Current fiscal year (ends Mar 2027) | $0.91 | $0.93 | -1.6% | $2.36T | 2 |
| Next fiscal year (ends Mar 2028) | $1.14 | $1.08 | +5.9% | $2.40T | 1 |
Key Statistics (as of October 23, 2026 at 16:42 UTC)
| Price | USD 17.83 |
|---|---|
| Change | ▼ 1.44% (down) |
| Previous Close | USD 18.09 |
| Open | USD 17.87 |
| Day Range | USD 17.83 – 17.92 |
| 52-Week Range | USD 14.98 – 26.8 |
| Volume | 5,314 shares |
| Market Cap | $32.44B |
| Exchange | PNK |
Technical Analysis (DSNKY)
Nexqual's technical model rates DSNKY "BUY" based on 4 bullish and 1 bearish signals across 128 daily candles, as of October 23, 2026 at 16:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.56 (neutral) |
| vs SMA50 | Above (USD 17.81) |
| MACD | -0.04 (negative) |
Analyst Ratings (DSNKY)
Wall Street analysts rate DSNKY "Buy" based on 2 analysts, with a mean price target of USD 23.35 (range USD 22–24.7), per Nexqual as of October 23, 2026 at 16:42 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 23.35 |
| High Target | USD 24.7 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (DSNKY)
| Next Earnings Date | 2026-10-30 |
|---|---|
| Revenue Estimate | $566.08B |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Financials & Fundamentals (DSNKY)
| Total Revenue | $2.22T |
|---|---|
| Revenue Growth (latest quarter, YoY) | +21.10% |
| Gross Margin | +68.47% |
| Operating Margin | +14.81% |
| Profit Margin | +10.93% |
| ROE | +14.81% |
| Debt / Equity | 0.29 |
| Current Ratio | 2.92 |
| Total Cash | $637.85B |
| Total Debt | $500.48B |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Financial Health Score (DSNKY)
Nexqual rates Daiichi Sankyo Company, Limited's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 16:42 UTC.
| Growth | Solid — Revenue +13% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 15% (last 12 months) |
| Balance Sheet | Strong — JPY 637.9B cash vs JPY 500.5B debt, net cash position |
| Cash Flow | Solid — Operating cash flow JPY 134.6B (TTM) |
| Efficiency | Mixed — ROE 15%, ROA 3.3% |
Ownership (DSNKY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.02% |
| Shares Outstanding | 1.82B |
| Float | 1.82B |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Leadership (DSNKY)
Daiichi Sankyo Company, Limited is led by Hiroyuki Okuzawa, President, CEO & Representative Director, per Nexqual as of October 23, 2026 at 16:42 UTC.
| President, CEO & Representative Director | Hiroyuki Okuzawa |
|---|---|
| Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director | Takashi Matsumoto |
| Head of Oncology Business Unit & Global Oncology Business and Director | Joseph Kenneth Keller |
| Senior Executive Officer, Head of Global Corporate Planning & Management and CFO | Tomohiro Kodama |
| Corporate Officer, Head of Business Transformation & CTO | Tetsuya Ohira |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIIB | Biogen Inc. | USD 250.88 | ▼ 1.17% |
| SNY | Sanofi | USD 41.51 | ▼ 1.07% |
| GSK | GSK plc | USD 50.66 | ▼ 1.08% |
| BMY | Bristol-Myers Squibb Company | USD 61.82 | ▼ 1.87% |
| PFE | Pfizer, Inc. | USD 30.08 | ▼ 1.13% |
| NVO | Novo Nordisk A/S | USD 39.06 | ▼ 0.95% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:42 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt